case₹100 Crpage 408
Balaji Steroids & Hormones Pvt Ltd civil suit against Company in Indore Court (July 11, 2026) seeking ₹1,000 million damages for alleged defamation via offer document disclosures
ListedMainboardPharmaceuticals & DrugsSYMBIOTEC
Symbiotec Pharmalab IPO
Symbiotec Pharmalab IPO is a mainboard IPO raising ₹1,757 Cr at ₹938 – ₹988 a share. It listed on 1 Sept 2026 at ₹988, 0.0% against its issue price of ₹988, and trades at ₹1,139 today (+15.3% since issue). It was subscribed 71× in total.
₹988
Issue price
₹1,139
Price now
+15.3%
Since issue price
1 Sept 2026
Listed on
71×Subscribed (final) · all exchanges
71.3 times more demand than shares on offer
populated partly populated we hold nothing here — the tab says why
What’s in court
The issuer’s own summary of outstanding legal proceedings — SEBI requires this table in every prospectus. Counts and amounts are as disclosed; the disclosed aggregate at stake is ₹152 Cr.
| Against | Criminal | Tax | Other material | Amount at stake |
|---|---|---|---|---|
| The company | 1 | 6 | 1 | ₹151 Cr |
| Subsidiaries | 0 | 1 | 1 | ₹0.4 Cr |
| Directors | 3 | 11 | 0 | ₹0.4 Cr |
| Promoters | 1 | 1 | 1 | — |
| Group companies | 0 | 0 | 0 | — |
case₹23 Crpage 408
Income Tax section 148A(1) re-assessment notice to Company for AY 2021-22 alleging ₹226.63 million short levy under section 115BAA; order under 148A(3) passed June 27, 2026
casepage 407
FIR dated Nov 7, 2017 filed by Company against former employees and Balaji Steroids promoter Prem Aldasani for alleged theft of confidential technical data (API formulations); chargesheet filed Feb 23, 2020, matter pending; also basis for Prem Aldasani's quashing plea against Promoter Anil Satwani and BSH writ petition seeking to halt the Offer
All amounts stated in ₹ million in the prospectus; converted to ₹ crore (1 crore = 10 million). Total amount computed from stated tax tables (Company ₹507.92M + Company other ₹1,000M + Subsidiaries ₹3.67M + Directors ₹4.12M = ₹1,515.71M ≈ ₹151.571 crore); no grand total is explicitly stated in the document. Company has no group companies. Promoter tax case count is 1 with amount not quantified (Nil). Criminal counts aggregate 'By' and 'Against' for each party. Subsidiary 'other' case (Knovea Pharmaceutical writ petition challenging land reclassification) has no quantifiable amount. Director matters include legacy/associated-company cases (e.g., GCPL/Tapi Pristresd) where the Director is named by virtue of prior board positions.. Outstanding means unresolved — a listed case is an exposure, not a verdict.
Source documents
What the issuer and the exchanges published. Everything else on this tab is read out of these.
Prospectus on SEBI ↗
The full prospectus — business, financials, risk factors and litigation.
Anchor investor allocation ↗
Which institutions were allotted shares before bidding opened, and how many.
Bidding centres ↗
Where physical applications could be submitted.
Basis of issue price (peer ratios) ↗
The issuer's own "basis of issue price": the earnings multiples it is asking for, and the peer companies it chose to compare itself against.
Red Herring Prospectus ↗
The full prospectus — business, financials, risk factors and litigation.